The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
p53 isoforms can regulate p53 transcriptional activity
Open accessAbstract
The recently discovered p53-related genes, p73 and p63, express multiple splice variants and N-terminally truncated forms initiated from an alternative promoter in intron 3. To date, no alternative promoter and multiple splice variants have been described for the p53 gene. In this study, we show that p53 has a gene structure similar to the p73 and p63 genes. The human p53 gene contains an alternative promoter and transcribes multiple splice variants. We show that p53 variants are expressed in normal human tissue in a tissue-dependent manner. We determine that the alternative promoter is conserved through evolution from Drosophila to man, suggesting that the p53 family gene structure plays an essential role in the multiple activities of the p53 family members. Consistent with this hypothesis, p53 variants are differentially expressed in human breast tumors compared with normal breast tissue. We establish that p53β can bind differentially to promoters and can enhance p53 target gene expression in a promoter-dependent manner, while Δ133p53 is dominant-negative toward full-length p53, inhibiting p53-mediated apoptosis. The differential expression of the p53 isoforms in human tumors may explain the difficulties in linking p53 status to the biological properties and drug sensitivity of human cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Among them are p53β, a C-terminally truncated isoform that cooperates with p53FL, and Δ133p53, an N-terminally truncated isoform that inhibits p53FL in a dominant-negative manner (14).”
From p53 isoforms regulate aging- and tumor-associated replicative senescence in T lymphocytes (2013) · cites this paper as [14]
In the citing paper
“these data suggest a mechanism by which Δ133p53, which lacks the transactivation domain (14), transcriptionally activates CD28 mRNA expression.”
From p53 isoforms regulate aging- and tumor-associated replicative senescence in T lymphocytes (2013) · cites this paper as [14]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antibodies, a laboratory manual
(1989) · Biomedicine & Pharmacotherapy · doi:10.1016/0753-3322(89)90130-3 · Cited by 12,318
T antigen is bound to a host protein in SY40-transformed cells
Lane, D. P., & Crawford, L. V. (1979) · Nature · doi:10.1038/278261a0 · Cited by 2,456
Self-citationLinzer, D. I. H., & Levine, A. J. (1979) · Cell · doi:10.1016/0092-8674(79)90293-9 · Cited by 1,814
p53 mutant mice that display early ageing-associated phenotypes
Tyner, S. D., Venkatachalam, S., Choi, J., Jones, S., Ghebranious, N., Igelmann, H., Lu, X., Soron, G., Cooper, B., Brayton, C., et al. (2002) · Nature · doi:10.1038/415045a · Cited by 1,459
Decision making by p53: life, death and cancer
Oren, M. (2003) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401183 · Cited by 1,085
DeLeo, A. B., Jay, G. D., Appella, E., DuBois, G. C., Law, L. W., & Old, L. J. (1979) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.76.5.2420 · Cited by 721
Modulation of mammalian life span by the short isoform of p53
Maier, B., Gluba, W., Bernier, B., Turner, T., Mohammad, K., Guise, T., Sutherland, A., Thorner, M., & Scrable, H. (2004) · Genes & Development · doi:10.1101/gad.1162404 · Cited by 586
Mdm2-Mediated NEDD8 Conjugation of p53 Inhibits Its Transcriptional Activity
Xirodimas, D. P., Saville, M. K., Bourdon, J.-C., Hay, R. T., & Lane, D. P. (2004) · Cell · doi:10.1016/j.cell.2004.06.016 · Cited by 570
Self-citationOn the shoulders of giants: p63, p73 and the rise of p53
Yang, A., Kaghad, M., Caput, D., & McKeon, F. (2002) · Trends in Genetics · doi:10.1016/s0168-9525(02)02595-7 · Cited by 496
Drosophila p53 Binds a Damage Response Element at the reaper Locus
Brodsky, M. H., Nordstrom, W., Tsang, G., Kwan, E., Rubin, G. M., & Abrams, J. (2000) · Cell · doi:10.1016/s0092-8674(00)80627-3 · Cited by 474
Flagged first, then by citations
Research works printed but not linked: 7
- 1996, Oncogene, 12, 813
- 1986, Mol. Cell. Biol., 6, 1379
- 2003, Cell Death Differ., 1, 431
- 1995, Oncogene, 10, 1865
- 1995, Oncogene, 10, 389
- 1985, Mol. Cell. Biol., 5, 127
- 2003, Cancer Res., 63, 2351
Cited by
Sorted by citations
Items 101–200 of 807
p53 ancestry: gazing through an evolutionary lens
Lu, W.-J., Amatruda, J. F., & Abrams, J. M. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2732 · Cited by 112
Circular RNA circEsyt2 regulates vascular smooth muscle cell remodeling via splicing regulation
Gong, X., Tian, M., Cao, N., Yang, P., Xu, Z., Zheng, S., Liao, Q., Chen, C., Zeng, C., José, P. A., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci147031 · Cited by 112
Skarie, J. M., & Link, B. A. (2008) · Human Molecular Genetics · doi:10.1093/hmg/ddn147 · Cited by 119
p53/p63/p73 in the Epidermis in Health and DiseasePreprint
Botchkarev, V. A., & Flores, E. R. (2014) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a015248 · Cited by 111
Candeias, M. M., Powell, D. J., Roubalová, E., Apcher, S., Bourougaa, K., Vojtěšek, B., Bruzzoni‐Giovanelli, H., & Fåhræus, R. (2006) · Oncogene · doi:10.1038/sj.onc.1209996 · Cited by 118
Molecular genetics of supratentorial primitive neuroectodermal tumors and pineoblastoma
Li, M. H., Bouffet, É., Hawkins, C. E., Squire, J. A., & Huang, A. (2005) · Neurosurgical FOCUS · doi:10.3171/foc.2005.19.5.4 · Cited by 111
p53 on the crossroad between regeneration and cancer
Charni‐Natan, M., Aloni-Grinstein, R., Molchadsky, A., & Rotter, V. (2016) · Cell Death and Differentiation · doi:10.1038/cdd.2016.117 · Cited by 115
Gong, L., Gong, H., Pan, X., Chang, C., Ou, Z., Ye, S., Yin, L., Yang, L., Tao, T., Zhang, Z., et al. (2015) · Cell Research · doi:10.1038/cr.2015.22 · Cited by 115
Self-citationBourdon, J., Khoury, M. P., Diot, A., Baker, L., Fernandes, K., Aoubala, M., Quinlan, P., Purdie, C. A., Jordan, L. B., Prats, A., et al. (2011) · Breast Cancer Research · doi:10.1186/bcr2811 · Cited by 110
Self-citationAnczuków, O., Ware, M. D., Buisson, M., Zetoune, A. B., Stoppa‐Lyonnet, D., Sinilnikova, O. M., & Mazoyer, S. (2007) · Human Mutation · doi:10.1002/humu.20590 · Cited by 108
Mehta, S., Christopherson, K. W., Bhat‐Nakshatri, P., Goulet, R. J., Broxmeyer, H. E., Kopelovich, L., & Nakshatri, H. (2006) · Oncogene · doi:10.1038/sj.onc.1210120 · Cited by 109
p63: oncogene or tumor suppressor?
Mills, A. A. (2005) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2005.12.001 · Cited by 107
Adamia, S., Haibe-Kains, B., Pilarski, P. M., Bar-Natan, M., Pevzner, S., Avet-Loiseau, H., Lode, L., Verselis, S., Fox, E. A., Burke, J., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0956 · Cited by 106
Uversky, V. N. (2014) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2014.00006 · Cited by 108
Positive feedback between p53 and TRF2 during telomere-damage signalling and cellular senescence
Fujita, K., Horikawa, I., Mondal, A. M., Jenkins, L. M. M., Appella, E., Vojtěšek, B., Bourdon, J., Lane, D. P., & Harris, C. C. (2010) · Nature Cell Biology · doi:10.1038/ncb2123 · Cited by 111
Self-citationΔ40p53 controls the switch from pluripotency to differentiation by regulating IGF signaling in ESCsPreprint
Ungewitter, E. K., & Scrable, H. J. (2010) · Genes & Development · doi:10.1101/gad.1987810 · Cited by 101
Alternative splicing in cancers: From aberrant regulation to new therapeutics
Song, X., Zeng, Z., Wei, H. Y., & Wang, Z. (2017) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2017.09.018 · Cited by 103
The interactions of p53 with tau and Aß as potential therapeutic targets for Alzheimer’s disease
Jembrek, M. J., Slade, N., Hof, P. R., & Šimić, G. (2018) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2018.05.001 · Cited by 101
HMGA1 Inhibits the Function of p53 Family Members in Thyroid Cancer Cells
Frasca, F., Rustighi, A., Malaguarnera, R., Altamura, S., Vigneri, P. G., Sal, G. D., Giancotti, V., PEZZINO, V., Vigneri, R., & Manfioletti, G. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2637 · Cited by 100
Molecular Mechanisms of p53 Deregulation in Cancer: An Overview in Multiple Myeloma
Herrero, A. B., Rojas, E. A., Misiewicz-Krzemińska, I., Krzemiński, P., & Gutierrez, N. C. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17122003 · Cited by 102
RHAMM is differentially expressed in the cell cycle and downregulated by the tumor suppressor p53
Sohr, S., & Engeland, K. (2008) · Cell Cycle · doi:10.4161/cc.7.21.7014 · Cited by 103
The Role of p53 Gene Family in ReproductionPreprint
Hu, W. (2009) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a001073 · Cited by 104
p53 Family: Role of Protein Isoforms in Human Cancer
Wei, J., Zaika, E. I., & Zaika, A. I. (2012) · Journal of Nucleic Acids · doi:10.1155/2012/687359 · Cited by 102
p53 is activated in response to disruption of the pre-mRNA splicing machinery
Allende-Vega, N., Dayal, S., Agarwala, U., Sparks, A., Bourdon, J., & Saville, M. K. (2012) · Oncogene · doi:10.1038/onc.2012.38 · Cited by 98
Self-citationChoi, J. W., Kim, D. G., Lee, A.-E., Kim, H., Lee, J. Y., Kwon, N. H., Shin, Y. K., Hwang, S.-K., Chang, S.-H., Cho, M., et al. (2011) · PLoS Genetics · doi:10.1371/journal.pgen.1001351 · Cited by 96
Regulation of mammalian transcription and splicing by Nuclear RNAi
Kalantari, R., Chiang, C., & Corey, D. R. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv1305 · Cited by 100
Marcel, V., Fernandes, K., Terrier, O., Lane, D. P., & Bourdon, J. (2014) · Cell Death and Differentiation · doi:10.1038/cdd.2014.73 · Cited by 97
Self-citationUnleashing the power of p53: lessons from mice and men: Figure 1.Preprint
Poyurovsky, M. V., & Prives, C. L. (2006) · Genes & Development · doi:10.1101/gad.1397506 · Cited by 96
p53-based cancer therapies: is defective p53 the Achilles heel of the tumor?
Levesque, A. A., & Eastman, A. R. (2006) · Carcinogenesis · doi:10.1093/carcin/bgl214 · Cited by 95
Hasty, P., Sharp, Z. D., Curiel, T. J., & Campisi, J. (2012) · Cell Cycle · doi:10.4161/cc.22912 · Cited by 92
p53 Is Cleaved by Caspases Generating Fragments Localizing to Mitochondria
Sayan, B. S., Sayan, E., Knight, R. A., Melino, G., & Cohen, G. M. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m512467200 · Cited by 94
Horikawa, I., Fujita, K., Jenkins, L. M. M., Hiyoshi, Y., Mondal, A. M., Vojtěšek, B., Lane, D. P., Appella, E., & Harris, C. C. (2014) · Nature Communications · doi:10.1038/ncomms5706 · Cited by 100
Self-citationTargeting cellular senescence in cancer and aging: roles of p53 and its isoforms
Beck, J. A., Turnquist, C., Horikawa, I., & Harris, C. C. (2020) · Carcinogenesis · doi:10.1093/carcin/bgaa071 · Cited by 97
Şentürk, Ş., Yao, Z., Camiolo, M. J., Stiles, B. M., Rathod, T., Walsh, A. M., Nemajerová, A., Lazzara, M. J., Altorki, N. K., Krainer, A. R., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1321640111 · Cited by 92
Ånensen, N., Oyan, A. M., Bourdon, J., Kalland, K. H., Bruserud, Ø., & Gjertsen, B. T. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1970 · Cited by 94
Self-citationLeroy, B., Ballinger, M. L., Baran‐Marszak, F., Bond, G. L., Braithwaite, A. W., Concin, N., Donehower, L. A., El‐Deiry, W. S., Fenaux, P., Gaïdano, G., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2179 · Cited by 95
Sbisà, E., Catalano, D., Grillo, G., Licciulli, F., Turi, A., Liuni, S., Pesole, G., Grassi, A., Caratozzolo, M. F., D’Erchia, A. M., et al. (2007) · BMC Bioinformatics · doi:10.1186/1471-2105-8-s1-s20 · Cited by 90
Brachova, P., Mueting, S. R., Carlson, M. J., Goodheart, M. J., Button, A. M., Mott, S. L., Dai, D. D., Thiel, K. W., Devor, E. J., & Leslie, K. K. (2014) · International Journal of Oncology · doi:10.3892/ijo.2014.2747 · Cited by 87
The emerging era of genomic data integration for analyzing splice isoform function
Li, H. D., Menon, R., Omenn, G. S., & Guan, Y. (2014) · Trends in Genetics · doi:10.1016/j.tig.2014.05.005 · Cited by 86
Pehar, M., O’Riordan, K. J., Burns‐Cusato, M., Andrzejewski, M. E., del Alcazar, C. R. G., Bürger, C., Scrable, H. J., & Puglielli, L. (2010) · Aging Cell · doi:10.1111/j.1474-9726.2010.00547.x · Cited by 89
Tumor suppression by p53: making cells senescent.
Qian, Y., & Chen, X. (2010) · PubMed · doi:10.14670/hh-25.515 · Cited by 85
The Emerging Landscape of p53 Isoforms in Physiology, Cancer and Degenerative Diseases
Anbarasan, T., & Bourdon, J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20246257 · Cited by 85
Self-citationCurcumin Regulates Cancer Progression: Focus on ncRNAs and Molecular Signaling Pathways
Wang, H., Zhang, K., Liu, J., Yang, J., Tian, Y., Chen, Y., Li, Y., Shao, M., Su, W., & Song, N. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.660712 · Cited by 89
Versatile functions of p53 protein in multicellular organisms
Chumakov, P. M. (2007) · Biochemistry (Moscow) · doi:10.1134/s0006297907130019 · Cited by 85
Why do centenarians escape or postpone cancer? The role of IGF-1, inflammation and p53
Salvioli, S., Capri, M., Bucci, L., Lanni, C., Racchi, M., Uberti, D. L., Memo, M., Mari, D., Govoni, S. M., & Franceschi, C. (2009) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-008-0639-6 · Cited by 87
The p53 isoform, Δ133p53α, stimulates angiogenesis and tumour progression
Bernard, H., Garmy-Susini, B. H., Ainaoui, N., Berghe, L. V. D., Peurichard, A., Javerzat, S., Bikfalvi, A., Lane, D. P., Bourdon, J., & Prats, A. (2012) · Oncogene · doi:10.1038/onc.2012.242 · Cited by 83
Self-citationAvery‐Kiejda, K. A., Morten, B. C., Wong‐Brown, M. W., Mathe, A., & Scott, R. J. (2013) · Carcinogenesis · doi:10.1093/carcin/bgt411 · Cited by 83
Laptenko, O., Tong, D. R., Manfredi, J. J., & Prives, C. L. (2016) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2016.08.011 · Cited by 88
Moulder, D. E., Hatoum, D., Tay, E. S. E., Lin, Y., & McGowan, E. M. (2018) · Cancers · doi:10.3390/cancers10060189 · Cited by 87
Hofstetter, G., Berger, A., Fiegl, H., Slade, N., Zorić, A., Holzer, B., Schuster, E., Möbus, V. J., Reimer, D., Daxenbichler, G., et al. (2010) · Oncogene · doi:10.1038/onc.2009.482 · Cited by 82
Wild-type p53 in cancer cells: When a guardian turns into a blackguard
Kim, E. L., Giese, A., & Deppert, W. (2008) · Biochemical Pharmacology · doi:10.1016/j.bcp.2008.08.030 · Cited by 83
Dual roles of Drosophila p53 in cell death and cell differentiation
Fan, Y., Lee, T. V., Xu, D., Chen, Z., Lamblin, A.-F., Steller, H., & Bergmann, A. (2009) · Cell Death and Differentiation · doi:10.1038/cdd.2009.182 · Cited by 86
Expression of p53 isoforms in squamous cell carcinoma of the head and neck
Boldrup, L., Bourdon, J., Coates, P. J., Sjöström, B., & Nylander, K. (2007) · European Journal of Cancer · doi:10.1016/j.ejca.2006.10.019 · Cited by 81
Self-citationSmall Molecule Inhibition of HDM2 Leads to p53-Mediated Cell Death in Retinoblastoma Cells
Elison, J. R. (2006) · Archives of Ophthalmology · doi:10.1001/archopht.124.9.1269 · Cited by 81
Role of p53 isoforms and aggregations in cancer
Kim, S., & An, S. S. A. (2016) · Medicine · doi:10.1097/md.0000000000003993 · Cited by 81
The role of MDM2 and MDM4 in breast cancer development and prevention
Haupt, S., Vijayakumaran, R., Miranda, P. J., Burgess, A., Lim, E., & Haupt, Y. (2017) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjx007 · Cited by 83
p53: link to the past, bridge to the futurePreprint
Mills, A. A. (2005) · Genes & Development · doi:10.1101/gad.1362905 · Cited by 81
Alternative splicings on p53, BRCA1 and PTEN genes involved in breast cancer
Okumura, N., Yoshida, H., Kitagishi, Y., Nishimura, Y., & Matsuda, S. (2011) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2011.08.098 · Cited by 80
Mlynarczyk, C., & Fåhræus, R. (2014) · Nature Communications · doi:10.1038/ncomms6067 · Cited by 80
p53 family proteins in thyroid cancer
Malaguarnera, R., Vella, V., Vigneri, R., & Frasca, F. (2007) · Endocrine Related Cancer · doi:10.1677/erc.1.01223 · Cited by 80
Antagonistic pleiotropy and p53
Ungewitter, E. K., & Scrable, H. J. (2008) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2008.06.002 · Cited by 88
Expression of C-terminal deleted p53 isoforms in neuroblastoma
Goldschneider, D., Horvilleur, E., Plassa, L., Guillaud-Bataille, M., Million, K., Evelyne, W.-D., Danglot, G., de Thé, H., Bénard, J., May, E., et al. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkl619 · Cited by 80
The Paradox of p53: What, How, and Why?Preprint
Aylon, Y., & Oren, M. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026328 · Cited by 81
Translational approaches targeting the p53 pathway for anti‐cancer therapy
Essmann, F., & Schulze‐Osthoff, K. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01570.x · Cited by 77
Myomegalin is necessary for the formation of centrosomal and Golgi-derived microtubules
Roubin, R., Acquaviva, C., Chevrier, V., Sedjaï, F., Zyss, D., Birnbaum, D., & Rosnet, O. (2012) · Biology Open · doi:10.1242/bio.20123392 · Cited by 79
Campbell, H. G., Fleming, N. I., Roth, I. M., Mehta, S. Y., Wiles, A. K., Williams, G., Vennin, C., Arsic, N., Parkin, A., Pajic, M., et al. (2018) · Nature Communications · doi:10.1038/s41467-017-02408-0 · Cited by 81
Ribi, S., Baumhoer, D., Lee, K., Edison, Teo, A. S. M., Madan, B., Zhang, K., Kohlmann, W. K., Yao, F., Lee, W. H., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3115 · Cited by 75
Marcel, V., Vijayakumar, V., Fernandez‐Cuesta, L., Hafsi, H., Sagne, C., Hautefeuille, A. H., Olivier, M., & Hainaut, P. L. (2010) · Oncogene · doi:10.1038/onc.2010.26 · Cited by 79
cncRNAs: Bi-functional RNAs with protein coding and non-coding functions
Kumari, P., & Sampath, K. (2015) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2015.10.024 · Cited by 77
Jordan, J. J., Inga, A., Conway, K., Edmiston, S. N., Carey, L., Wu, L., & Resnick, M. A. (2010) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-09-0442 · Cited by 77
Ubiquitin and Ubiquitin-Like Modifications of the p53 Family
Watson, I. R., & Irwin, M. S. (2006) · Neoplasia · doi:10.1593/neo.06439 · Cited by 77
Bourdon, J. (2007) · Current Pharmaceutical Biotechnology · doi:10.2174/138920107783018444 · Cited by 81
Self-citationp53 prevents neurodegeneration by regulating synaptic genes
Merlo, P., Frost, B. E., Peng, S., Yang, Y. J., Park, P. J., & Feany, M. Β. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1419083111 · Cited by 77
30 years and a long way into p53 research
Hainaut, P. L., & Wiman, K. G. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70198-6 · Cited by 80
Horikawa, I., Park, K., Isogaya, K., Hiyoshi, Y., Li, H., Anami, K., Robles, A. I., Mondal, A. M., Fujita, K., Serrano, M., et al. (2017) · Cell Death and Differentiation · doi:10.1038/cdd.2017.48 · Cited by 76
Galluzzi, L., Morselli, E., Kepp, O., Vitale, I., Pinti, M., & Kroemer, G. (2010) · Antioxidants and Redox Signaling · doi:10.1089/ars.2010.3504 · Cited by 83
p53 isoforms - A conspiracy to kidnap p53 tumor suppressor activity?
Marcel, V., & Hainaut, P. L. (2008) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-008-8336-3 · Cited by 79
DNA double-strand breaks: A potential causative factor for mammalian aging?
Li, H., Mitchell, J. R., & Hasty, P. (2008) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2008.02.002 · Cited by 76
P53 and its molecular basis to chemoresistance in breast cancer
Knappskog, S., & Lønning, P. E. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2011.640322 · Cited by 73
p53 family members in cancer diagnosis and treatment
Machado-Silva, A., Perrier, S., & Bourdon, J. (2010) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2010.02.005 · Cited by 73
Self-citationp53: at the crossroad between cancer and ageing
Papazoglu, C., & Mills, A. (2007) · The Journal of Pathology · doi:10.1002/path.2086 · Cited by 75
Hyperproliferation, cancer, and inflammation in mice expressing a Δ133p53-like isoform
Slatter, T. L., Hung, N. A., Campbell, H. G., Rubio, C., Mehta, R., Renshaw, P., Williams, G., Wilson, M., Engelmann, A., Jeffs, A. R., et al. (2011) · Blood · doi:10.1182/blood-2010-11-321851 · Cited by 76
The p53 control of apoptosis and proliferation: lessons from Drosophila
Mollereau, B., & Ma, D. (2014) · APOPTOSIS · doi:10.1007/s10495-014-1035-7 · Cited by 71
Okuyama, R., Ogawa, E., Nagoshi, H., Yabuki, M., Kurihara, A., Terui, T., Aiba, S., Obinata, M., Tagami, H., & Ikawa, S. (2007) · Oncogene · doi:10.1038/sj.onc.1210235 · Cited by 71
Advanced Strategies for Therapeutic Targeting of Wild-Type and Mutant p53 in Cancer
Zhang, S., Carlsen, L., Borrero, L. J. H., Seyhan, A. A., Tian, X., & El‐Deiry, W. S. (2022) · Biomolecules · doi:10.3390/biom12040548 · Cited by 75
Mechanistic differences in the transcriptional activation of p53 by 14-3-3 isoforms
Rajagopalan, S., Sade, R. S., Townsley, F. M., & Fersht, A. R. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkp1041 · Cited by 72
The genetic basis of tissue responses to ionizing radiation
Lindsay, K. J., Coates, P. J., Lorimore, S. A., & Wright, E. G. (2007) · British Journal of Radiology · doi:10.1259/bjr/60507340 · Cited by 70
Silva, J. L., Rangel, L. P., da Costa, D. C. F., Cordeiro, Y., & Gallo, C. V. D. M. (2013) · Bioscience Reports · doi:10.1042/bsr20130065 · Cited by 72
Oncogenic Intra-p53 Family Member Interactions in Human Cancers
Ferraiuolo, M. A., Agostino, S. D., Blandino, G., & Strano, S. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00077 · Cited by 72
p53-mediated apoptosis of CLL cells: evidence for a transcription-independent mechanism
Steele, A. J., Prentice, A. G., Hoffbrand, A. V., Yogashangary, B. C., Hart, S., Nacheva, E. P., Howard‐Reeves, J., Duke, V. M., Kottaridis, P. D., Cwynarski, K., et al. (2008) · Blood · doi:10.1182/blood-2008-05-156380 · Cited by 69
Edmondson, R., Adcock, A. F., & Yang, L. (2016) · PLoS ONE · doi:10.1371/journal.pone.0158116 · Cited by 69
Assessing p53 in clinical contexts: unlearned lessons and new perspectives
Hall, P. A., & McCluggage, W. G. (2005) · The Journal of Pathology · doi:10.1002/path.1913 · Cited by 69
TP53 drives invasion through expression of its Δ133p53β variant
Gadéa, G., Arsic, N., Fernandes, K., Diot, A., Joruiz, S. M., Abdallah, S., Meuray, V., Vinot, S., Anguille, C., Reményi, J., et al. (2016) · eLife · doi:10.7554/elife.14734 · Cited by 71
Self-citationWaskar, M., Landis, G. N., Shen, J., Curtis, C. N., Tozer, K. R., Abdueva, D. A., Skvortsov, D., Tavaré, S., & Tower, J. (2009) · Aging · doi:10.18632/aging.100099 · Cited by 67
Zhang, B., Mehrotra, S., Ng, W. L., & Calvi, B. R. (2014) · PLoS Genetics · doi:10.1371/journal.pgen.1004581 · Cited by 71
Lunardi, A., Minin, G. D., Provero, P., Ferro, M. D., Carotti, M., Sal, G. D., & Collavin, L. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1002447107 · Cited by 66
Def defines a conserved nucleolar pathway that leads p53 to proteasome-independent degradation
Tao, T., Shi, H., Guan, Y., Huang, D., Chen, Y., Lane, D. P., Chen, J., & Peng, J. (2013) · Cell Research · doi:10.1038/cr.2013.16 · Cited by 67
Self-citationMarchese, E., Vignati, A., Albanese, A., Nucci, C. G., Sabatino, G., Tirpakova, B., Lofrese, G., Zelano, G., & Maira, G. (2010) · PubMed · Cited by 67
p53 isoforms regulate premature aging in human cells
von Muhlinen, N., Horikawa, I., Alam, F., Isogaya, K., Lissa, D., Vojtesek, B., Lane, D. P., & Harris, C. C. (2018) · Oncogene · doi:10.1038/s41388-017-0101-3 · Cited by 70
Self-citationTzvetkov, M. V., Meineke, C., Oetjen, E., Hirsch‐Ernst, K. I., & Brockmöller, J. (2006) · Gene · doi:10.1016/j.gene.2006.08.002 · Cited by 67
Metadata
- Authors
- Bourdon, J.-C., Fernandes, K., Murray-Zmijewski, F., Liu, G., Diot, A., Xirodimas, D. P., Saville, M. K., & Lane, D. P.
- Affiliations
- University of Dundee (GB)
- ORCID
- Venue
- Genes & Development
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2005-08-30
- Volume
- 19
- Issue
- 18
- Pages
- 2122-2137
- ISSN
- 0890-9369 (ISSN-L)
- 1549-5477
- PMC
- PMC1221884
- OpenAlex
- W2155570392
- Cited by
- 810
- References
- 43
- Citations by year
- 2026: 19 · 2025: 30 · 2024: 26 · 2023: 30 · 2022: 25 · 2021: 37 · 2020: 29 · 2019: 28 · 2018: 41 · 2017: 27 · 2016: 40 · 2015: 27 · 2014: 49 · 2013: 38 · 2012: 48
- Type
- posted content
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Genes & Development (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Discovery Research Portal (University of Dundee) (publishedVersion)
- HAL (submittedVersion)
- HighWire Press Open Archive (submittedVersion)
- Genes
- Funders
- Medical Research Council
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Keywords
- p53 isoforms, alternative promoters, p73, p63, Δ133p53, dominant-negative p53, p53 transcriptional activity, breast tumors, Drosophila, apoptosis, cancer drug sensitivity
- MeSH terms
- Animals, Breast Neoplasms, Drosophila, Humans, Introns, Luciferases, Promoter Regions, Genetic, RNA, Messenger, Transcription, Genetic, Genetic Variation, Gene Expression Regulation, Neoplastic, Genes, p53, Tumor Suppressor Protein p53, Apoptosis, Genes, Insect, Alternative Splicing, Genes, Reporter, HT29 Cells, Evolution, Molecular, Protein Isoforms, Reverse Transcriptase Polymerase Chain Reaction, Cell Line, Tumor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
